Chief, Infectious Diseases Unit
Juan A. Fernandez Hospital
Professor of Infectious Diseases
Buenos Aires University Medical School
Buenos Aires, Argentina
- Access to care
- Antiretroviral therapy
- Opportunistic infections/tuberculosis
- Perinatal transmission
Dr Cahn is Chief of the Infectious Diseases Unit at the Juan A. Fernandez Hospital in Buenos Aires, Argentina. He is a Professor of Infectious Diseases at the Buenos Aires University Medical School, and the Scientific Director of the Huésped Foundation.
- Member, Governing Council, International AIDS Society
- Member, Advisory Board, National AIDS Program, Argentina
- Chair, the 1st International AIDS Society Conference on HIV Pathogenesis and Treatment, Buenos Aires (2001)
- Chair, Group 1 (Clinical Care), The International Meeting on Access to Care for People Living with HIV/AIDS, Dakar, Senegal (2001)
- Co-chair, Track B (Clinical Sciences), The XIVth International Conference on AIDS, Barcelona (2002)
- European School of Oncology: Cancer and AIDS (1995)
- National Academy of Surgery (Argentina): Anal Diseases in HIV (1996)
- Selected as Independent Investigator by the Buenos Aires City Health Council (2001)
- University of Buenos Aires Medical School, MD (1971)
- Juan A. Fernandez Hospital, Residency in Internal Medicine (1972–1975)
- University of Buenos Aires Medical School, Board Certification in Infectious Diseases (1978)
- University of Buenos Aires Medical School, PhD (1984)
- Warren RQ, Wong MT, Melcher GP, Blatt SP, Cahn P, Perez H, Zapiola I, Bouzas MB, Muchinik G, Anderson SA, et al. Serologic evaluation of human immunodeficiency virus type 1-infected individuals from Argentina and the United States indicates a similar distribution of subgroup B isolates. J Clin Microbiol. 1995;33:481-483.
- Casariego Z, Kelly GR, Perez H, Cahn P, Guelfan L, Kaufman S, Scully C. Disseminated histoplasmosis with orofacial involvement in HIV-I-infected patients with AIDS: manifestations and treatment. Oral Dis. 1997;3:184-187.
- Cahn P. Is highly active antiretroviral therapy unaffordable in the developing world? The case of South America. HIV & AIDS Current Trends. 1998;4:1-3. Mediscript, London.
- Pagano MA, Segura MJ, Di Lorenzo GA, Garau ML, Molina HA, Cahn P, Perez H, Vitolo F, Grondona A, Piedimonte FC, Giannaula R, Ramia R, Miranda MA, Sierra H, Sica RE. Cerebral tumor-like American trypanosomiasis in acquired immunodeficiency syndrome. Ann Neurol. 1999;45:403-406.
- Fainboim H, Gonzalez J, Fassio E, Martinez A, Otegui L, Eposto M, Cahn P, Marino R, Landeira G, Suaya G, Gancedo E, Castro R, Brajterman L, Laplume H. Prevalence of hepatitis viruses in an anti-human immunodeficiency virus-positive population from Argentina. A multicentre study. J Viral Hepat. 1999;6:53-57.
- Zala C, Salomón H, Cahn P. Treatment of primary HIV infection: a pilot study of stavudine and didanosine plus nevirapine with or without hydroxyurea. Antivir Ther. 1999;4(suppl 2):95-99.
- Cahn P, Belloso WH, Murillo J, Prada-Trujillo G. AIDS in Latin America. Infect Dis Clin North Am. 2000;14:185-209. Review.
- Losso MH, Belloso WH, Emery S, Benetucci JA, Cahn PE, Lasala MC, Lopardo G, Salomon H, Saracco M, Nelson E, Law MG, Davey RT, Allende MC, Lane HC. A randomized, controlled, phase II trial comparing escalating doses of subcutaneous interleukin-2 plus antiretrovirals versus antiretrovirals alone in human immunodeficiency virus-infected patients with CD4+ cell counts >/=350/mm3. J Infect Dis. 2000;181:1614-1621.
- Zala C, Ochoa C, Krolewiecki A, Patterson P, Cahn P, Crawford RI, Montaner JS. Highly active antiretroviral therapy does not protect against Kaposi's sarcoma in HIV-infected individuals. AIDS. 2000;14:2217-2218.
- Cahn P. Access to treatment for HIV: new actors in an old drama. HIV & AIDS Current Trends. 2001;7:1-3. Mediscript, London.
Thompson MA, Aberg JA, Hoy JF, Telenti A, Benson C, Cahn P, Eron JJ, Gunthard HF, Hammer SH, Reiss P, Richman DD, Rizzardini G, Thomas DL, Jacobsen DM, Volberding PA. Antiretroviral Treatment of Adult HIV Infection: 2012 Recommendations of the International Antiviral Society–USA Panel. JAMA. 2012;308(4):387-402. PMID: 22820792. (See announcement)